CASI Pharma Secures Asset Freeze Against Juventas
Ticker: CASIF · Form: 6-K · Filed: Jul 19, 2024 · CIK: 1962738
| Field | Detail |
|---|---|
| Company | Casi Pharmaceuticals, INC. (CASIF) |
| Form Type | 6-K |
| Filed Date | Jul 19, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: legal-action, asset-freeze, dispute
Related Tickers: CASI
TL;DR
CASI got a court to freeze Juventas' assets over that $10.5M dispute.
AI Summary
On July 19, 2024, CASI Pharmaceuticals, Inc. announced it obtained an asset freezing order from a court in the People's Republic of China against Juventas. This action is related to a previous dispute where CASI sought to recover approximately $10.5 million from Juventas.
Why It Matters
This legal action aims to protect CASI's potential recovery of a significant sum, indicating a serious dispute with a former partner.
Risk Assessment
Risk Level: medium — The asset freeze is a positive step, but the ultimate recovery of funds from Juventas remains uncertain and subject to further legal proceedings.
Key Numbers
- $10.5M — Amount in Dispute (CASI is seeking to recover this amount from Juventas.)
Key Players & Entities
- CASI Pharmaceuticals, Inc. (company) — Filer of the report and party seeking asset freeze
- Juventas (company) — Party against whom the asset freeze was obtained
- July 19, 2024 (date) — Date the asset freezing order was obtained
- $10.5 million (dollar_amount) — Amount CASI sought to recover from Juventas
FAQ
What is the specific reason for the asset freezing order against Juventas?
The asset freezing order is related to CASI's prior legal action to recover approximately $10.5 million from Juventas.
When was the asset freezing order obtained?
The asset freezing order was obtained on July 19, 2024.
What is the total amount CASI is seeking from Juventas?
CASI is seeking to recover approximately $10.5 million from Juventas.
In which jurisdiction was the asset freezing order granted?
The asset freezing order was granted by a court in the People's Republic of China.
What is the relationship between CASI Pharmaceuticals, Inc. and Juventas?
The filing implies a dispute between CASI and Juventas, with CASI taking legal action to recover funds from Juventas.
Filing Stats: 549 words · 2 min read · ~2 pages · Grade level 12.5 · Accepted 2024-07-19 06:07:25
Filing Documents
- tm2419826d1_6k.htm (6-K) — 11KB
- 0001104659-24-080958.txt ( ) — 13KB
Forward-Looking Statements
Forward-Looking Statements This 6-K contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking herein.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CASI Pharmaceuticals, Inc. By: /s/ Wei-Wu He Name: Wei-Wu He Title: Chairman & CEO Date: July 19, 2024